Purpose: The efficacy of tocilizumab in refractory chronic noninfectious uveitis has been previously reported, but no data comparing intravenous and subcutaneous tocilizumab in uveitis are available.
Results: We report a case series of patients with chronic noninfectious uveitis with incomplete efficacy of subcutaneous tocilizumab, improved after switching to intravenous routes. Improvement of visual acuity was observed with intravenous tocilizumab for all patients. Half of the patients could stop corticosteroids. Rapid efficacy of intravenous tocilizumab was observed, between 2 and 3 months.
Conclusion: In uveitis, tocilizumab administration could be optimized by a switching from a subcutaneous to an intravenous administration route.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354347 | PMC |
| http://dx.doi.org/10.1186/s12348-023-00336-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Associations of genetic polymorphisms with clinical response to tocilizumab in Chinese rheumatoid arthritis patients.
Int Immunopharmacol
December 2024
Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China. Electronic address:
Objective: To examine the associations of single-nucleotide polymorphisms (SNPs) within interleukin-6 (IL6) and IL-6 receptor (IL6R) as well as several potential SNPs revealed in a genome-wide association study (GWAS) with clinical response to tocilizumab (TCZ) in Chinese rheumatoid arthritis (RA) patients.
Methods: A total of 23 SNPs were genotyped in 68 RA patients receiving intravenous TCZ, who were prospectively followed for 6 months to determine the clinical response based on several criteria, including clinical disease activity index (CDAI) low disease activity (LDA) and remission, disease activity score in 28 joint counts - erythrocyte sedimentation rate (DAS28-ESR) LDA and remission, European League Against Rheumatism (EULAR) good response and change in DAS28-ESR (ΔDAS28-ESR).
Results: The patients were on average 51.
Cytokine Release Syndrome After CAR T-Cell Therapy in a 35-Year-Old Patient With Pneumonia and Cytomegalovirus Viremia.
Case Rep Med
December 2024
BMT/Hematology, Mayo Clinic, Rochester, Minnesota, USA.
The risk of cytokine release syndrome (CRS) in patients with infections prior to chimeric antigen receptor T-cell (CAR T-cell) therapy represents an important and underreported event. Patients with active infections needing prompt CAR T-cell therapy to treat aggressive hematologic malignancies remain a clinical challenge. This case describes the clinical course of a 35-year-old male patient with relapsed/refractory T-cell/histiocyte-rich large B-cell lymphoma who received axicabtagene ciloleucel.
View Article and Find Full Text PDFEarly initiation of intravenous cyclophosphamide and one-year outcome in super-refractory cryptogenic-new onset refractory status epilepticus.
Epilepsia Open
December 2024
Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
To explore the potential efficacy of early initiation of intravenous cyclophosphamide (IVCPA), we reviewed consecutive four cases of super-refractory cryptogenic-new onset refractory status epilepticus (C-NORSE) between 2015 and 2023. We compared functional outcomes at 3 months and 1 year after the onset between patients who received IVCPA within 20 days (early-treated) and those who received it later (late-treated). All patients (median age: 43 years) had a prodromal fever.
View Article and Find Full Text PDFCase Series on the Efficacy and Safety of Tocilizumab in IVIG-Resistant Kawasaki Disease: A Retrospective Analysis of Five Patients.
J Inflamm Res
December 2024
Department of Rheumatology and Immunology, Jiangxi Children's Hospital, Jiangxi Medical College, Nanchang, Jiangxi, People's Republic of China.
Background: Kawasaki disease (KD) is a leading cause of acquired heart disease in children in developed countries. While intravenous immunoglobulin (IVIG) is the standard treatment, 10-20% of patients do not respond to IVIG. Given the significant role of interleukin-6 (IL-6) in KD pathophysiology, targeting IL-6 may offer a therapeutic option for IVIG-resistant KD.
View Article and Find Full Text PDFParaneoplastic Syndromes of the Nervous System in Patients Suffering from SCLC. A Review of the Recent Literature.
Acta Med Acad
August 2024
Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Background: Paraneoplastic Neurological Syndromes (PNS) constitute a heterogeneous cluster of disease manifestations related to various cancers. Small Cell Lung Cancer (SCLC) is strongly related to PNS. This narrative review conducted a survey in the available PubMed literature to highlight the appearance of PNSs in SCLC cases and discuss published research highlights on the subject so that general practitioners can be acquainted with the medical phenomenon present in SCLC patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!